Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clonidine is a centrally acting alpha-2 adrenergic agonist and small molecule antihypertensive agent. It lowers blood pressure by stimulating alpha-2 adrenoceptors in the brainstem, which decreases sympathetic outflow from the central nervous system. This results in reduced heart rate and relaxation of blood vessels. Clonidine is used to treat hypertension (high blood pressure), either alone or with other medications. Extended-release formulations are also approved for attention deficit hyperactivity disorder (ADHD) in children 6 years and older by affecting brain regions involved in attention and impulsivity. Additional uses include management of severe cancer pain (as an adjunct), withdrawal symptoms from opioids or other substances, migraine prevention, diagnosis of pheochromocytoma, Tourette's syndrome, menopausal symptoms such as hot flashes, and certain pain syndromes[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clonidine.